source name	characteristics[organism]	characteristics[organism part]	characteristics[Sample type]	characteristics[cell type]	characteristics[ancestry category]	characteristics[age]	characteristics[sex]	characteristics[disease]	characteristics[individual]	characteristics[biological replicate]	technology type	assay name	comment[technical replicate]	comment[data file]	comment[file uri]	comment[fraction identifier]	comment[label]	comment[instrument]	comment[cleavage agent details]	comment[cleavage agent details]	comment[modification parameters]	comment[modification parameters]	comment[modification parameters]	comment[dissociation method]	comment[precursor mass tolerance]	comment[fragment mass tolerance]	comment[collision energy]	factor value[disease]
PXD015289-sample-1	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p1	1	proteomic profiling by mass spectrometry	run1	1	180815_Bert_A1EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_A1EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-1	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p1	1	proteomic profiling by mass spectrometry	run2	2	180815_Bert_A1EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_A1EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-1	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p1	1	proteomic profiling by mass spectrometry	run3	3	180815_Bert_A1EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_A1EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-2	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p2	2	proteomic profiling by mass spectrometry	run4	1	180815_Bert_B1EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_B1EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-2	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p2	2	proteomic profiling by mass spectrometry	run5	2	180815_Bert_B1EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_B1EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-2	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p2	2	proteomic profiling by mass spectrometry	run6	3	180815_Bert_B1EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_B1EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-3	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p3	3	proteomic profiling by mass spectrometry	run7	1	180815_Bert_C1EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_C1EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-3	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p3	3	proteomic profiling by mass spectrometry	run8	2	180815_Bert_C1EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_C1EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-3	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p3	3	proteomic profiling by mass spectrometry	run9	3	180815_Bert_C1EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_C1EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-4	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p4	4	proteomic profiling by mass spectrometry	run10	1	180815_Bert_D1EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_D1EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-4	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p4	4	proteomic profiling by mass spectrometry	run11	2	180815_Bert_D1EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_D1EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-4	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p4	4	proteomic profiling by mass spectrometry	run12	3	180815_Bert_D1EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_D1EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-5	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p5	5	proteomic profiling by mass spectrometry	run13	1	180815_Bert_E1EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_E1EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-5	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p5	5	proteomic profiling by mass spectrometry	run14	2	180815_Bert_E1EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_E1EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-5	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p5	5	proteomic profiling by mass spectrometry	run15	3	180815_Bert_E1EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_E1EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-6	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p6	6	proteomic profiling by mass spectrometry	run16	1	180815_Bert_F1EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_F1EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-6	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p6	6	proteomic profiling by mass spectrometry	run17	2	180815_Bert_F1EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_F1EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-6	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p6	6	proteomic profiling by mass spectrometry	run18	3	180815_Bert_F1EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_F1EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-7	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p7	7	proteomic profiling by mass spectrometry	run19	1	180815_Bert_G1EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_G1EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-7	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p7	7	proteomic profiling by mass spectrometry	run20	2	180815_Bert_G1EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_G1EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-7	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p7	7	proteomic profiling by mass spectrometry	run21	3	180815_Bert_G1EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_G1EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-8	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p8	8	proteomic profiling by mass spectrometry	run22	1	180815_Bert_H1EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_H1EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-8	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p8	8	proteomic profiling by mass spectrometry	run23	2	180815_Bert_H1EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_H1EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-8	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p8	8	proteomic profiling by mass spectrometry	run24	3	180815_Bert_H1EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_H1EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-9	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p9	9	proteomic profiling by mass spectrometry	run25	1	180815_Bert_I1EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_I1EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-9	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p9	9	proteomic profiling by mass spectrometry	run26	2	180815_Bert_I1EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_I1EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-9	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p9	9	proteomic profiling by mass spectrometry	run27	3	180815_Bert_I1EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_I1EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-10	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p10	10	proteomic profiling by mass spectrometry	run28	1	180815_Bert_J1EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_J1EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-10	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p10	10	proteomic profiling by mass spectrometry	run29	2	180815_Bert_J1EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_J1EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-10	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p10	10	proteomic profiling by mass spectrometry	run30	3	180815_Bert_J1EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_J1EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-11	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p11	11	proteomic profiling by mass spectrometry	run31	1	180815_Bert_K1EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_K1EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-11	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p11	11	proteomic profiling by mass spectrometry	run32	2	180815_Bert_K1EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_K1EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-11	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p11	11	proteomic profiling by mass spectrometry	run33	3	180815_Bert_K1EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_K1EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-12	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p12	12	proteomic profiling by mass spectrometry	run34	1	180815_Bert_L1EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_L1EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-12	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p12	12	proteomic profiling by mass spectrometry	run35	2	180815_Bert_L1EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_L1EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-12	Homo sapiens	Urine	Prostate cancer pre-treatment: EV enriched	not available	not available	not available	male	Prostate cancer	p12	12	proteomic profiling by mass spectrometry	run36	3	180815_Bert_L1EV_3_180817132239.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_L1EV_3_180817132239.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-13	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p13	1	proteomic profiling by mass spectrometry	run37	1	180815_Bert_A1SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_A1SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-13	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p13	1	proteomic profiling by mass spectrometry	run38	2	180815_Bert_A1SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_A1SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-13	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p13	1	proteomic profiling by mass spectrometry	run39	3	180815_Bert_A1SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_A1SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-14	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p14	2	proteomic profiling by mass spectrometry	run40	1	180815_Bert_B1SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_B1SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-14	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p14	2	proteomic profiling by mass spectrometry	run41	2	180815_Bert_B1SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_B1SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-14	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p14	2	proteomic profiling by mass spectrometry	run42	3	180815_Bert_B1SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_B1SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-15	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p15	3	proteomic profiling by mass spectrometry	run43	1	180815_Bert_C1SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_C1SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-15	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p15	3	proteomic profiling by mass spectrometry	run44	2	180815_Bert_C1SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_C1SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-15	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p15	3	proteomic profiling by mass spectrometry	run45	3	180815_Bert_C1SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_C1SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-16	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p16	4	proteomic profiling by mass spectrometry	run46	1	180815_Bert_D1SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_D1SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-16	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p16	4	proteomic profiling by mass spectrometry	run47	2	180815_Bert_D1SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_D1SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-16	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p16	4	proteomic profiling by mass spectrometry	run48	3	180815_Bert_D1SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_D1SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-17	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p17	5	proteomic profiling by mass spectrometry	run49	1	180815_Bert_E1SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_E1SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-17	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p17	5	proteomic profiling by mass spectrometry	run50	2	180815_Bert_E1SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_E1SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-17	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p17	5	proteomic profiling by mass spectrometry	run51	3	180815_Bert_E1SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_E1SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-18	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p18	6	proteomic profiling by mass spectrometry	run52	1	180815_Bert_F1SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_F1SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-18	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p18	6	proteomic profiling by mass spectrometry	run53	2	180815_Bert_F1SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_F1SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-18	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p18	6	proteomic profiling by mass spectrometry	run54	3	180815_Bert_F1SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_F1SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-19	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p19	7	proteomic profiling by mass spectrometry	run55	1	180815_Bert_G1SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_G1SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-19	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p19	7	proteomic profiling by mass spectrometry	run56	2	180815_Bert_G1SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_G1SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-19	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p19	7	proteomic profiling by mass spectrometry	run57	3	180815_Bert_G1SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_G1SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-20	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p20	8	proteomic profiling by mass spectrometry	run58	1	180815_Bert_H1SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_H1SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-20	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p20	8	proteomic profiling by mass spectrometry	run59	2	180815_Bert_H1SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_H1SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-20	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p20	8	proteomic profiling by mass spectrometry	run60	3	180815_Bert_H1SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_H1SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-21	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p21	9	proteomic profiling by mass spectrometry	run61	1	180815_Bert_I1SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_I1SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-21	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p21	9	proteomic profiling by mass spectrometry	run62	2	180815_Bert_I1SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_I1SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-21	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p21	9	proteomic profiling by mass spectrometry	run63	3	180815_Bert_I1SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_I1SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-22	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p22	10	proteomic profiling by mass spectrometry	run64	1	180815_Bert_J1SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_J1SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-22	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p22	10	proteomic profiling by mass spectrometry	run65	2	180815_Bert_J1SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_J1SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-22	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p22	10	proteomic profiling by mass spectrometry	run66	3	180815_Bert_J1SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_J1SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-23	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p23	11	proteomic profiling by mass spectrometry	run67	1	180815_Bert_K1SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_K1SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-23	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p23	11	proteomic profiling by mass spectrometry	run68	2	180815_Bert_K1SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_K1SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-23	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p23	11	proteomic profiling by mass spectrometry	run69	3	180815_Bert_K1SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_K1SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-24	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p24	12	proteomic profiling by mass spectrometry	run70	1	180815_Bert_L1SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_L1SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-24	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p24	12	proteomic profiling by mass spectrometry	run71	2	180815_Bert_L1SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_L1SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-24	Homo sapiens	Urine	Prostate cancer pre-treatment: Protein enriched	not available	not available	not available	male	Prostate cancer	p24	12	proteomic profiling by mass spectrometry	run72	3	180815_Bert_L1SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_L1SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-25	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p25	1	proteomic profiling by mass spectrometry	run73	1	180815_Bert_A2EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_A2EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-25	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p25	1	proteomic profiling by mass spectrometry	run74	2	180815_Bert_A2EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_A2EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-25	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p25	1	proteomic profiling by mass spectrometry	run75	3	180815_Bert_A2EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_A2EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-26	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p26	2	proteomic profiling by mass spectrometry	run76	1	180815_Bert_B2EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_B2EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-26	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p26	2	proteomic profiling by mass spectrometry	run77	2	180815_Bert_B2EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_B2EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-26	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p26	2	proteomic profiling by mass spectrometry	run78	3	180815_Bert_B2EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_B2EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-27	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p27	3	proteomic profiling by mass spectrometry	run79	1	180815_Bert_C2EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_C2EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-27	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p27	3	proteomic profiling by mass spectrometry	run80	2	180815_Bert_C2EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_C2EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-27	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p27	3	proteomic profiling by mass spectrometry	run81	3	180815_Bert_C2EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_C2EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-28	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p28	4	proteomic profiling by mass spectrometry	run82	1	180815_Bert_D2EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_D2EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-28	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p28	4	proteomic profiling by mass spectrometry	run83	2	180815_Bert_D2EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_D2EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-28	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p28	4	proteomic profiling by mass spectrometry	run84	3	180815_Bert_D2EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_D2EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-29	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p29	5	proteomic profiling by mass spectrometry	run85	1	180815_Bert_E2EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_E2EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-29	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p29	5	proteomic profiling by mass spectrometry	run86	2	180815_Bert_E2EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_E2EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-29	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p29	5	proteomic profiling by mass spectrometry	run87	3	180815_Bert_E2EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_E2EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-30	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p30	6	proteomic profiling by mass spectrometry	run88	1	180815_Bert_F2EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_F2EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-30	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p30	6	proteomic profiling by mass spectrometry	run89	2	180815_Bert_F2EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_F2EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-30	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p30	6	proteomic profiling by mass spectrometry	run90	3	180815_Bert_F2EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_F2EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-31	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p31	7	proteomic profiling by mass spectrometry	run91	1	180815_Bert_G2EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_G2EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-31	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p31	7	proteomic profiling by mass spectrometry	run92	2	180815_Bert_G2EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_G2EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-31	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p31	7	proteomic profiling by mass spectrometry	run93	3	180815_Bert_G2EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_G2EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-32	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p32	8	proteomic profiling by mass spectrometry	run94	1	180815_Bert_H2EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_H2EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-32	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p32	8	proteomic profiling by mass spectrometry	run95	2	180815_Bert_H2EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_H2EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-32	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p32	8	proteomic profiling by mass spectrometry	run96	3	180815_Bert_H2EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_H2EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-33	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p33	9	proteomic profiling by mass spectrometry	run97	1	180815_Bert_J2EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_J2EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-33	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p33	9	proteomic profiling by mass spectrometry	run98	2	180815_Bert_J2EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_J2EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-33	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p33	9	proteomic profiling by mass spectrometry	run99	3	180815_Bert_J2EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_J2EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-34	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p34	10	proteomic profiling by mass spectrometry	run100	1	180815_Bert_L2EV_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_L2EV_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-34	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p34	10	proteomic profiling by mass spectrometry	run101	2	180815_Bert_L2EV_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_L2EV_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-34	Homo sapiens	Urine	Prostate cancer post-treatment: EV enriched	not available	not available	not available	male	Prostate cancer post-treatment	p34	10	proteomic profiling by mass spectrometry	run102	3	180815_Bert_L2EV_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_L2EV_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-35	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p35	1	proteomic profiling by mass spectrometry	run103	1	180815_Bert_A2SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_A2SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-35	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p35	1	proteomic profiling by mass spectrometry	run104	2	180815_Bert_A2SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_A2SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-35	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p35	1	proteomic profiling by mass spectrometry	run105	3	180815_Bert_A2SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_A2SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-36	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p36	2	proteomic profiling by mass spectrometry	run106	1	180815_Bert_B2SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_B2SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-36	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p36	2	proteomic profiling by mass spectrometry	run107	2	180815_Bert_B2SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_B2SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-36	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p36	2	proteomic profiling by mass spectrometry	run108	3	180815_Bert_B2SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_B2SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-37	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p37	3	proteomic profiling by mass spectrometry	run109	1	180815_Bert_C2SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_C2SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-37	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p37	3	proteomic profiling by mass spectrometry	run110	2	180815_Bert_C2SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_C2SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-37	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p37	3	proteomic profiling by mass spectrometry	run111	3	180815_Bert_C2SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_C2SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-38	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p38	4	proteomic profiling by mass spectrometry	run112	1	180815_Bert_D2SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_D2SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-38	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p38	4	proteomic profiling by mass spectrometry	run113	2	180815_Bert_D2SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_D2SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-38	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p38	4	proteomic profiling by mass spectrometry	run114	3	180815_Bert_D2SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_D2SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-39	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p39	5	proteomic profiling by mass spectrometry	run115	1	180815_Bert_E2SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_E2SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-39	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p39	5	proteomic profiling by mass spectrometry	run116	2	180815_Bert_E2SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_E2SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-39	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p39	5	proteomic profiling by mass spectrometry	run117	3	180815_Bert_E2SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_E2SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-40	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p40	6	proteomic profiling by mass spectrometry	run118	1	180815_Bert_F2SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_F2SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-40	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p40	6	proteomic profiling by mass spectrometry	run119	2	180815_Bert_F2SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_F2SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-40	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p40	6	proteomic profiling by mass spectrometry	run120	3	180815_Bert_F2SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_F2SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-41	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p41	7	proteomic profiling by mass spectrometry	run121	1	180815_Bert_G2SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_G2SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-41	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p41	7	proteomic profiling by mass spectrometry	run122	2	180815_Bert_G2SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_G2SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-41	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p41	7	proteomic profiling by mass spectrometry	run123	3	180815_Bert_G2SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_G2SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-42	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p42	8	proteomic profiling by mass spectrometry	run124	1	180815_Bert_H2SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_H2SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-42	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p42	8	proteomic profiling by mass spectrometry	run125	2	180815_Bert_H2SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_H2SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-42	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p42	8	proteomic profiling by mass spectrometry	run126	3	180815_Bert_H2SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_H2SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-43	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p43	9	proteomic profiling by mass spectrometry	run127	1	180815_Bert_J2SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_J2SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-43	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p43	9	proteomic profiling by mass spectrometry	run128	2	180815_Bert_J2SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_J2SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-43	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p43	9	proteomic profiling by mass spectrometry	run129	3	180815_Bert_J2SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_J2SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-44	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p44	10	proteomic profiling by mass spectrometry	run130	1	180815_Bert_L2SP_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_L2SP_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-44	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p44	10	proteomic profiling by mass spectrometry	run131	2	180815_Bert_L2SP_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_L2SP_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-44	Homo sapiens	Urine	Prostate cancer post-treatment: protein enriched	not available	not available	not available	male	Prostate cancer post-treatment	p44	10	proteomic profiling by mass spectrometry	run132	3	180815_Bert_L2SP_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180815_Bert_L2SP_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer post-treatment
PXD015289-sample-45	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p45	1	proteomic profiling by mass spectrometry	run133	1	190225_PekkaR_HCEV1_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV1_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-45	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p45	1	proteomic profiling by mass spectrometry	run134	2	190225_PekkaR_HCEV1_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV1_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-45	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p45	1	proteomic profiling by mass spectrometry	run135	3	190225_PekkaR_HCEV1_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV1_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-46	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p46	2	proteomic profiling by mass spectrometry	run136	1	190225_PekkaR_HCEV2_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV2_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-46	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p46	2	proteomic profiling by mass spectrometry	run137	2	190225_PekkaR_HCEV2_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV2_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-46	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p46	2	proteomic profiling by mass spectrometry	run138	3	190225_PekkaR_HCEV2_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV2_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-47	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p47	3	proteomic profiling by mass spectrometry	run139	1	190225_PekkaR_HCEV3_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV3_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-47	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p47	3	proteomic profiling by mass spectrometry	run140	2	190225_PekkaR_HCEV3_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV3_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-47	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p47	3	proteomic profiling by mass spectrometry	run141	3	190225_PekkaR_HCEV3_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV3_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-48	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p48	4	proteomic profiling by mass spectrometry	run142	1	190225_PekkaR_HCEV4_1_20190225162742.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV4_1_20190225162742.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-48	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p48	4	proteomic profiling by mass spectrometry	run143	2	190225_PekkaR_HCEV4_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV4_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-48	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p48	4	proteomic profiling by mass spectrometry	run144	3	190225_PekkaR_HCEV4_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV4_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-49	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p49	5	proteomic profiling by mass spectrometry	run145	1	190225_PekkaR_HCEV5_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV5_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-49	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p49	5	proteomic profiling by mass spectrometry	run146	2	190225_PekkaR_HCEV5_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV5_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-49	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p49	5	proteomic profiling by mass spectrometry	run147	3	190225_PekkaR_HCEV5_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV5_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-50	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p50	6	proteomic profiling by mass spectrometry	run148	1	190225_PekkaR_HCEV6_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV6_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-50	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p50	6	proteomic profiling by mass spectrometry	run149	2	190225_PekkaR_HCEV6_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV6_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-50	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p50	6	proteomic profiling by mass spectrometry	run150	3	190225_PekkaR_HCEV6_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV6_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-51	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p51	7	proteomic profiling by mass spectrometry	run151	1	190225_PekkaR_HCEV7_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV7_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-51	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p51	7	proteomic profiling by mass spectrometry	run152	2	190225_PekkaR_HCEV7_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV7_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-51	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p51	7	proteomic profiling by mass spectrometry	run153	3	190225_PekkaR_HCEV7_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV7_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-52	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p52	8	proteomic profiling by mass spectrometry	run154	1	190225_PekkaR_HCEV8_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV8_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-52	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p52	8	proteomic profiling by mass spectrometry	run155	2	190225_PekkaR_HCEV8_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV8_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-52	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p52	8	proteomic profiling by mass spectrometry	run156	3	190225_PekkaR_HCEV8_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV8_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-53	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p53	9	proteomic profiling by mass spectrometry	run157	1	190225_PekkaR_HCEV9_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV9_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-53	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p53	9	proteomic profiling by mass spectrometry	run158	2	190225_PekkaR_HCEV9_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV9_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-53	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p53	9	proteomic profiling by mass spectrometry	run159	3	190225_PekkaR_HCEV9_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV9_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-54	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p54	10	proteomic profiling by mass spectrometry	run160	1	190225_PekkaR_HCEV10_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV10_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-54	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p54	10	proteomic profiling by mass spectrometry	run161	2	190225_PekkaR_HCEV10_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV10_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-54	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p54	10	proteomic profiling by mass spectrometry	run162	3	190225_PekkaR_HCEV10_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV10_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-55	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p55	11	proteomic profiling by mass spectrometry	run163	1	190225_PekkaR_HCEV11_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV11_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-55	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p55	11	proteomic profiling by mass spectrometry	run164	2	190225_PekkaR_HCEV11_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV11_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-55	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p55	11	proteomic profiling by mass spectrometry	run165	3	190225_PekkaR_HCEV11_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV11_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-56	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p56	12	proteomic profiling by mass spectrometry	run166	1	190225_PekkaR_HCEV12_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV12_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-56	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p56	12	proteomic profiling by mass spectrometry	run167	2	190225_PekkaR_HCEV12_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV12_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-56	Homo sapiens	Urine	Benign prostatic hyperplasia: EV enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p56	12	proteomic profiling by mass spectrometry	run168	3	190225_PekkaR_HCEV12_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190225_PekkaR_HCEV12_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-57	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p57	1	proteomic profiling by mass spectrometry	run169	1	190227_HCSP1_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP1_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-57	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p57	1	proteomic profiling by mass spectrometry	run170	2	190227_HCSP1_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP1_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-57	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p57	1	proteomic profiling by mass spectrometry	run171	3	190227_HCSP1_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP1_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-58	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p58	2	proteomic profiling by mass spectrometry	run172	1	190227_HCSP2_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP2_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-58	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p58	2	proteomic profiling by mass spectrometry	run173	2	190227_HCSP2_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP2_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-58	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p58	2	proteomic profiling by mass spectrometry	run174	3	190227_HCSP2_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP2_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-59	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p59	3	proteomic profiling by mass spectrometry	run175	1	190227_HCSP3_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP3_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-59	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p59	3	proteomic profiling by mass spectrometry	run176	2	190227_HCSP3_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP3_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-59	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p59	3	proteomic profiling by mass spectrometry	run177	3	190227_HCSP3_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP3_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-60	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p60	4	proteomic profiling by mass spectrometry	run178	1	190227_HCSP4_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP4_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-60	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p60	4	proteomic profiling by mass spectrometry	run179	2	190227_HCSP4_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP4_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-60	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p60	4	proteomic profiling by mass spectrometry	run180	3	190227_HCSP4_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP4_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-61	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p61	5	proteomic profiling by mass spectrometry	run181	1	190227_HCSP5_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP5_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-61	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p61	5	proteomic profiling by mass spectrometry	run182	2	190227_HCSP5_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP5_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-61	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p61	5	proteomic profiling by mass spectrometry	run183	3	190227_HCSP5_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP5_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-62	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p62	6	proteomic profiling by mass spectrometry	run184	1	190227_HCSP6_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP6_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-62	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p62	6	proteomic profiling by mass spectrometry	run185	2	190227_HCSP6_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP6_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-62	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p62	6	proteomic profiling by mass spectrometry	run186	3	190227_HCSP6_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP6_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-63	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p63	7	proteomic profiling by mass spectrometry	run187	1	190227_HCSP7_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP7_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-63	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p63	7	proteomic profiling by mass spectrometry	run188	2	190227_HCSP7_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP7_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-63	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p63	7	proteomic profiling by mass spectrometry	run189	3	190227_HCSP7_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP7_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-64	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p64	8	proteomic profiling by mass spectrometry	run190	1	190227_HCSP8_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP8_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-64	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p64	8	proteomic profiling by mass spectrometry	run191	2	190227_HCSP8_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP8_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-64	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p64	8	proteomic profiling by mass spectrometry	run192	3	190227_HCSP8_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP8_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-65	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p65	9	proteomic profiling by mass spectrometry	run193	1	190227_HCSP9_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP9_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-65	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p65	9	proteomic profiling by mass spectrometry	run194	2	190227_HCSP9_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP9_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-65	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p65	9	proteomic profiling by mass spectrometry	run195	3	190227_HCSP9_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP9_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-66	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p66	10	proteomic profiling by mass spectrometry	run196	1	190227_HCSP10_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP10_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-66	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p66	10	proteomic profiling by mass spectrometry	run197	2	190227_HCSP10_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP10_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-66	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p66	10	proteomic profiling by mass spectrometry	run198	3	190227_HCSP10_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP10_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-67	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p67	11	proteomic profiling by mass spectrometry	run199	1	190227_HCSP11_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP11_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-67	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p67	11	proteomic profiling by mass spectrometry	run200	2	190227_HCSP11_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP11_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-67	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p67	11	proteomic profiling by mass spectrometry	run201	3	190227_HCSP11_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP11_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-68	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p68	12	proteomic profiling by mass spectrometry	run202	1	190227_HCSP12_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP12_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-68	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p68	12	proteomic profiling by mass spectrometry	run203	2	190227_HCSP12_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP12_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-68	Homo sapiens	Urine	Benign prostatic hyperplasia: Protein enriched	not available	not available	not available	male	Benign prostatic hyperplasia	p68	12	proteomic profiling by mass spectrometry	run204	3	190227_HCSP12_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190227_HCSP12_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Benign prostatic hyperplasia
PXD015289-sample-69	Homo sapiens	Urine	Bladder cancer: EV enriched	not available	not available	not available	male	Bladder cancer	p69	1	proteomic profiling by mass spectrometry	run205	1	190301_UCEV1_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCEV1_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-69	Homo sapiens	Urine	Bladder cancer: EV enriched	not available	not available	not available	male	Bladder cancer	p69	1	proteomic profiling by mass spectrometry	run206	2	190301_UCEV1_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCEV1_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-69	Homo sapiens	Urine	Bladder cancer: EV enriched	not available	not available	not available	male	Bladder cancer	p69	1	proteomic profiling by mass spectrometry	run207	3	190301_UCEV1_4.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCEV1_4.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-70	Homo sapiens	Urine	Bladder cancer: EV enriched	not available	not available	not available	male	Bladder cancer	p70	2	proteomic profiling by mass spectrometry	run208	1	190301_UCEV2_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCEV2_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-70	Homo sapiens	Urine	Bladder cancer: EV enriched	not available	not available	not available	male	Bladder cancer	p70	2	proteomic profiling by mass spectrometry	run209	2	190301_UCEV2_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCEV2_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-70	Homo sapiens	Urine	Bladder cancer: EV enriched	not available	not available	not available	male	Bladder cancer	p70	2	proteomic profiling by mass spectrometry	run210	3	190301_UCEV2_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCEV2_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-71	Homo sapiens	Urine	Bladder cancer: EV enriched	not available	not available	not available	male	Bladder cancer	p71	3	proteomic profiling by mass spectrometry	run211	1	190301_UCEV3_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCEV3_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-71	Homo sapiens	Urine	Bladder cancer: EV enriched	not available	not available	not available	male	Bladder cancer	p71	3	proteomic profiling by mass spectrometry	run212	2	190301_UCEV3_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCEV3_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-71	Homo sapiens	Urine	Bladder cancer: EV enriched	not available	not available	not available	male	Bladder cancer	p71	3	proteomic profiling by mass spectrometry	run213	3	190301_UCEV3_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCEV3_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-72	Homo sapiens	Urine	Bladder cancer: EV enriched	not available	not available	not available	male	Bladder cancer	p72	4	proteomic profiling by mass spectrometry	run214	1	190301_UCEV5_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCEV5_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-72	Homo sapiens	Urine	Bladder cancer: EV enriched	not available	not available	not available	male	Bladder cancer	p72	4	proteomic profiling by mass spectrometry	run215	2	190301_UCEV5_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCEV5_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-72	Homo sapiens	Urine	Bladder cancer: EV enriched	not available	not available	not available	male	Bladder cancer	p72	4	proteomic profiling by mass spectrometry	run216	3	190301_UCEV5_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCEV5_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-73	Homo sapiens	Urine	Renal cancer: EV enriched	not available	not available	not available	male	Renal cancer	p73	1	proteomic profiling by mass spectrometry	run217	1	190301_RCEV1_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCEV1_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-73	Homo sapiens	Urine	Renal cancer: EV enriched	not available	not available	not available	male	Renal cancer	p73	1	proteomic profiling by mass spectrometry	run218	2	190301_RCEV1_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCEV1_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-73	Homo sapiens	Urine	Renal cancer: EV enriched	not available	not available	not available	male	Renal cancer	p73	1	proteomic profiling by mass spectrometry	run219	3	190301_RCEV1_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCEV1_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-74	Homo sapiens	Urine	Renal cancer: EV enriched	not available	not available	not available	male	Renal cancer	p74	2	proteomic profiling by mass spectrometry	run220	1	190301_RCEV2_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCEV2_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-74	Homo sapiens	Urine	Renal cancer: EV enriched	not available	not available	not available	male	Renal cancer	p74	2	proteomic profiling by mass spectrometry	run221	2	190301_RCEV2_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCEV2_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-74	Homo sapiens	Urine	Renal cancer: EV enriched	not available	not available	not available	male	Renal cancer	p74	2	proteomic profiling by mass spectrometry	run222	3	190301_RCEV2_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCEV2_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-75	Homo sapiens	Urine	Renal cancer: EV enriched	not available	not available	not available	male	Renal cancer	p75	3	proteomic profiling by mass spectrometry	run223	1	190301_RCEV3_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCEV3_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-75	Homo sapiens	Urine	Renal cancer: EV enriched	not available	not available	not available	male	Renal cancer	p75	3	proteomic profiling by mass spectrometry	run224	2	190301_RCEV3_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCEV3_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-75	Homo sapiens	Urine	Renal cancer: EV enriched	not available	not available	not available	male	Renal cancer	p75	3	proteomic profiling by mass spectrometry	run225	3	190301_RCEV3_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCEV3_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-76	Homo sapiens	Urine	Renal cancer: EV enriched	not available	not available	not available	male	Renal cancer	p76	4	proteomic profiling by mass spectrometry	run226	1	190301_RCEV4_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCEV4_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-76	Homo sapiens	Urine	Renal cancer: EV enriched	not available	not available	not available	male	Renal cancer	p76	4	proteomic profiling by mass spectrometry	run227	2	190301_RCEV4_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCEV4_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-76	Homo sapiens	Urine	Renal cancer: EV enriched	not available	not available	not available	male	Renal cancer	p76	4	proteomic profiling by mass spectrometry	run228	3	190301_RCEV4_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCEV4_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-77	Homo sapiens	Urine	Renal cancer: EV enriched	not available	not available	not available	male	Renal cancer	p77	5	proteomic profiling by mass spectrometry	run229	1	190301_RCEV5_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCEV5_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-77	Homo sapiens	Urine	Renal cancer: EV enriched	not available	not available	not available	male	Renal cancer	p77	5	proteomic profiling by mass spectrometry	run230	2	190301_RCEV5_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCEV5_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-77	Homo sapiens	Urine	Renal cancer: EV enriched	not available	not available	not available	male	Renal cancer	p77	5	proteomic profiling by mass spectrometry	run231	3	190301_RCEV5_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCEV5_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-78	Homo sapiens	Urine	Renal cancer: EV enriched	not available	not available	not available	male	Renal cancer	p78	6	proteomic profiling by mass spectrometry	run232	1	190301_RCEV6_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCEV6_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-78	Homo sapiens	Urine	Renal cancer: EV enriched	not available	not available	not available	male	Renal cancer	p78	6	proteomic profiling by mass spectrometry	run233	2	190301_RCEV6_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCEV6_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-78	Homo sapiens	Urine	Renal cancer: EV enriched	not available	not available	not available	male	Renal cancer	p78	6	proteomic profiling by mass spectrometry	run234	3	190301_RCEV6_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCEV6_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-79	Homo sapiens	Urine	Bladder cancer: protein enriched	not available	not available	not available	male	Bladder cancer	p79	1	proteomic profiling by mass spectrometry	run235	1	190301_UCSP1_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCSP1_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-79	Homo sapiens	Urine	Bladder cancer: protein enriched	not available	not available	not available	male	Bladder cancer	p79	1	proteomic profiling by mass spectrometry	run236	2	190301_UCSP1_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCSP1_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-79	Homo sapiens	Urine	Bladder cancer: protein enriched	not available	not available	not available	male	Bladder cancer	p79	1	proteomic profiling by mass spectrometry	run237	3	190301_UCSP1_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCSP1_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-80	Homo sapiens	Urine	Bladder cancer: protein enriched	not available	not available	not available	male	Bladder cancer	p80	2	proteomic profiling by mass spectrometry	run238	1	190301_UCSP2_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCSP2_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-80	Homo sapiens	Urine	Bladder cancer: protein enriched	not available	not available	not available	male	Bladder cancer	p80	2	proteomic profiling by mass spectrometry	run239	2	190301_UCSP2_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCSP2_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-80	Homo sapiens	Urine	Bladder cancer: protein enriched	not available	not available	not available	male	Bladder cancer	p80	2	proteomic profiling by mass spectrometry	run240	3	190301_UCSP2_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCSP2_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-81	Homo sapiens	Urine	Bladder cancer: protein enriched	not available	not available	not available	male	Bladder cancer	p81	3	proteomic profiling by mass spectrometry	run241	1	190301_UCSP3_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCSP3_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-81	Homo sapiens	Urine	Bladder cancer: protein enriched	not available	not available	not available	male	Bladder cancer	p81	3	proteomic profiling by mass spectrometry	run242	2	190301_UCSP3_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCSP3_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-81	Homo sapiens	Urine	Bladder cancer: protein enriched	not available	not available	not available	male	Bladder cancer	p81	3	proteomic profiling by mass spectrometry	run243	3	190301_UCSP3_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCSP3_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-82	Homo sapiens	Urine	Bladder cancer: protein enriched	not available	not available	not available	male	Bladder cancer	p82	4	proteomic profiling by mass spectrometry	run244	1	190301_UCSP5_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCSP5_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-82	Homo sapiens	Urine	Bladder cancer: protein enriched	not available	not available	not available	male	Bladder cancer	p82	4	proteomic profiling by mass spectrometry	run245	2	190301_UCSP5_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCSP5_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-82	Homo sapiens	Urine	Bladder cancer: protein enriched	not available	not available	not available	male	Bladder cancer	p82	4	proteomic profiling by mass spectrometry	run246	3	190301_UCSP5_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_UCSP5_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Bladder cancer
PXD015289-sample-83	Homo sapiens	Urine	Renal cancer: protein enriched	not available	not available	not available	male	Renal cancer	p83	1	proteomic profiling by mass spectrometry	run247	1	190301_RCSP1_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCSP1_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-83	Homo sapiens	Urine	Renal cancer: protein enriched	not available	not available	not available	male	Renal cancer	p83	1	proteomic profiling by mass spectrometry	run248	2	190301_RCSP1_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCSP1_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-83	Homo sapiens	Urine	Renal cancer: protein enriched	not available	not available	not available	male	Renal cancer	p83	1	proteomic profiling by mass spectrometry	run249	3	190301_RCSP1_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCSP1_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-84	Homo sapiens	Urine	Renal cancer: protein enriched	not available	not available	not available	male	Renal cancer	p84	2	proteomic profiling by mass spectrometry	run250	1	190301_RCSP2_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCSP2_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-84	Homo sapiens	Urine	Renal cancer: protein enriched	not available	not available	not available	male	Renal cancer	p84	2	proteomic profiling by mass spectrometry	run251	2	190301_RCSP2_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCSP2_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-84	Homo sapiens	Urine	Renal cancer: protein enriched	not available	not available	not available	male	Renal cancer	p84	2	proteomic profiling by mass spectrometry	run252	3	190301_RCSP2_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCSP2_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-85	Homo sapiens	Urine	Renal cancer: protein enriched	not available	not available	not available	male	Renal cancer	p85	3	proteomic profiling by mass spectrometry	run253	1	190301_RCSP3_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCSP3_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-85	Homo sapiens	Urine	Renal cancer: protein enriched	not available	not available	not available	male	Renal cancer	p85	3	proteomic profiling by mass spectrometry	run254	2	190301_RCSP3_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCSP3_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-85	Homo sapiens	Urine	Renal cancer: protein enriched	not available	not available	not available	male	Renal cancer	p85	3	proteomic profiling by mass spectrometry	run255	3	190301_RCSP3_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCSP3_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-86	Homo sapiens	Urine	Renal cancer: protein enriched	not available	not available	not available	male	Renal cancer	p86	4	proteomic profiling by mass spectrometry	run256	1	190301_RCSP4_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCSP4_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-86	Homo sapiens	Urine	Renal cancer: protein enriched	not available	not available	not available	male	Renal cancer	p86	4	proteomic profiling by mass spectrometry	run257	2	190301_RCSP4_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCSP4_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-86	Homo sapiens	Urine	Renal cancer: protein enriched	not available	not available	not available	male	Renal cancer	p86	4	proteomic profiling by mass spectrometry	run258	3	190301_RCSP4_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCSP4_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-87	Homo sapiens	Urine	Renal cancer: protein enriched	not available	not available	not available	male	Renal cancer	p87	5	proteomic profiling by mass spectrometry	run259	1	190301_RCSP5_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCSP5_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-87	Homo sapiens	Urine	Renal cancer: protein enriched	not available	not available	not available	male	Renal cancer	p87	5	proteomic profiling by mass spectrometry	run260	2	190301_RCSP5_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCSP5_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-87	Homo sapiens	Urine	Renal cancer: protein enriched	not available	not available	not available	male	Renal cancer	p87	5	proteomic profiling by mass spectrometry	run261	3	190301_RCSP5_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCSP5_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-88	Homo sapiens	Urine	Renal cancer: protein enriched	not available	not available	not available	male	Renal cancer	p88	6	proteomic profiling by mass spectrometry	run262	1	190301_RCSP6_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCSP6_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-88	Homo sapiens	Urine	Renal cancer: protein enriched	not available	not available	not available	male	Renal cancer	p88	6	proteomic profiling by mass spectrometry	run263	2	190301_RCSP6_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCSP6_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-88	Homo sapiens	Urine	Renal cancer: protein enriched	not available	not available	not available	male	Renal cancer	p88	6	proteomic profiling by mass spectrometry	run264	3	190301_RCSP6_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/190301_RCSP6_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Renal cancer
PXD015289-sample-89	Homo sapiens	Urine	Matched TIF EV	not available	not available	not available	male	Prostate cancer	p89	1	proteomic profiling by mass spectrometry	run265	1	180823_Bert_TIFA_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180823_Bert_TIFA_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-89	Homo sapiens	Urine	Matched TIF EV	not available	not available	not available	male	Prostate cancer	p89	1	proteomic profiling by mass spectrometry	run266	2	180823_Bert_TIFA_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180823_Bert_TIFA_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-89	Homo sapiens	Urine	Matched TIF EV	not available	not available	not available	male	Prostate cancer	p89	1	proteomic profiling by mass spectrometry	run267	3	180823_Bert_TIFA_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180823_Bert_TIFA_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-90	Homo sapiens	Urine	Matched TIF EV	not available	not available	not available	male	Prostate cancer	p90	2	proteomic profiling by mass spectrometry	run268	1	180823_Bert_TIFB_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180823_Bert_TIFB_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-90	Homo sapiens	Urine	Matched TIF EV	not available	not available	not available	male	Prostate cancer	p90	2	proteomic profiling by mass spectrometry	run269	2	180823_Bert_TIFB_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180823_Bert_TIFB_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-90	Homo sapiens	Urine	Matched TIF EV	not available	not available	not available	male	Prostate cancer	p90	2	proteomic profiling by mass spectrometry	run270	3	180823_Bert_TIFB_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180823_Bert_TIFB_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-91	Homo sapiens	Urine	Matched TIF EV	not available	not available	not available	male	Prostate cancer	p91	3	proteomic profiling by mass spectrometry	run271	1	180823_Bert_TIFC_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180823_Bert_TIFC_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-91	Homo sapiens	Urine	Matched TIF EV	not available	not available	not available	male	Prostate cancer	p91	3	proteomic profiling by mass spectrometry	run272	2	180823_Bert_TIFC_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180823_Bert_TIFC_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-91	Homo sapiens	Urine	Matched TIF EV	not available	not available	not available	male	Prostate cancer	p91	3	proteomic profiling by mass spectrometry	run273	3	180823_Bert_TIFC_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180823_Bert_TIFC_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-92	Homo sapiens	Urine	Matched urinary EV	not available	not available	not available	male	Prostate cancer	p92	1	proteomic profiling by mass spectrometry	run274	1	180823_Bert_UrA_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180823_Bert_UrA_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-92	Homo sapiens	Urine	Matched urinary EV	not available	not available	not available	male	Prostate cancer	p92	1	proteomic profiling by mass spectrometry	run275	2	180823_Bert_UrA_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180823_Bert_UrA_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-92	Homo sapiens	Urine	Matched urinary EV	not available	not available	not available	male	Prostate cancer	p92	1	proteomic profiling by mass spectrometry	run276	3	180823_Bert_UrA_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180823_Bert_UrA_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-93	Homo sapiens	Urine	Matched urinary EV	not available	not available	not available	male	Prostate cancer	p93	2	proteomic profiling by mass spectrometry	run277	1	180823_Bert_UrB_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180823_Bert_UrB_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-93	Homo sapiens	Urine	Matched urinary EV	not available	not available	not available	male	Prostate cancer	p93	2	proteomic profiling by mass spectrometry	run278	2	180823_Bert_UrB_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180823_Bert_UrB_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-93	Homo sapiens	Urine	Matched urinary EV	not available	not available	not available	male	Prostate cancer	p93	2	proteomic profiling by mass spectrometry	run279	3	180823_Bert_UrB_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180823_Bert_UrB_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-94	Homo sapiens	Urine	Matched urinary EV	not available	not available	not available	male	Prostate cancer	p94	3	proteomic profiling by mass spectrometry	run280	1	180823_Bert_UrC_1.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180823_Bert_UrC_1.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-94	Homo sapiens	Urine	Matched urinary EV	not available	not available	not available	male	Prostate cancer	p94	3	proteomic profiling by mass spectrometry	run281	2	180823_Bert_UrC_2.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180823_Bert_UrC_2.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
PXD015289-sample-94	Homo sapiens	Urine	Matched urinary EV	not available	not available	not available	male	Prostate cancer	p94	3	proteomic profiling by mass spectrometry	run282	3	180823_Bert_UrC_3.raw	ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD015289/180823_Bert_UrC_3.raw	1	NT=label free sample;AC=MS:1002038	NT=Q Exactive HF;AC=MS:1002523	NT=Trypsin;AC=MS:1001251	NT=Lys-C;AC=MS:1001309	NT=Carbamidomethyl;MT=Fixed;TA=C;AC=UNIMOD:4	NT=Acetyl;MT=Variable;TA=N-term;AC=UNIMOD:1	NT=Oxidation;MT=Variable;TA=M;AC=UNIMOD:35	HCD	not available	not available	27% NCE	Prostate cancer
